Latuda: ninth atypical antipsychotic reaches Canadian marketDrug is indicated for the acute treatment of schizophrenia and improves both positive and negative symptoms. Telemental health decreases psychiatric hospitalizationsFour-year study focused on U.S. veterans Light therapy: Early response does not predict long-term outcome Most patients with seasonal affective disorder respond after six weeks of treatment Aripiprazole depot injection delays schizophrenia relapse Once-monthly treatment may improve compliance Openers: CADTH Corner Uncharted territory for those with schizophrenia. Depressed? Stick needles in your head Acupuncture promising as add-on therapy There’s an app for... problem gambling New tools aim to reduce or stop harmful activity through self-monitoring Physiotherapists, psychologists to prescribe in Australia MDs fear proposal jeopardizes patient safety Saphris: new atypical antipsychotic New drug indicated for treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar I disorder. Depressed heart patients recover more slowly from exercise Sympathetic dysregulation may help explain worse outcomes in these patients First Previous 61 62 63 64 65 Next Last
